Multiple myeloma was initially termed “multiple” to distinguish it from plasmacytoma, a solitary tumor of a bone or an organ/tissue. Solitary plasmacytoma (SP) may develop further into a solitary plasmacytoma with minimal marrow involvement (SPMMI). Both SP and SPMMI are characterized by monoclo...
Interrogating MSigDB hallmark genesets, we found that pathways related to E2F targets, Notch signaling, G2M checkpoints, interferon alpha response, and Wnt/beta-catenin signaling are differentially enriched in abnormal samples compared to normal (t-testq < 0.1; Supplementary Fig.6a). To inves...
The primary aim was to determine the proportion of trials that collected MRD data within the ClinicalTrials.gov database. Secondary aims were to study the proportion of trials that used MRD as part of the inclusion criteria, as a primary, secondary and/or exploratory endpoint, and as a strati...
Blood Adv. 2024;8:1600–11. Article CAS PubMed Google Scholar Zhang X, et al. Characterization of CD4+ T cell-mediated cytotoxicity in patients with multiple myeloma. Cell Immunol. 2018;327:62–7. Article CAS PubMed Google Scholar Andreatta M, et al. Interpretation of T cell states ...
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. References 1. Siegel RL, Mi...
Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495–501 (2010). Article CAS PubMed PubMed Central Google Scholar Thomas, P. D. et al. PANTHER: Making genome‐scale phylogenetics accessible to all. Protein Sci. 31, 8–22 (2022). ...
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45(5):712–9. Article PubMed Google Scholar Nanni C. PET-FDG: impetus. Cancers Basel. 2020;12(4):1030. Article CAS ...
The subsequent blood test (in light of the speckles) uncovered the blood disorder.” Interval: Patient - 18 months; diagnostic – 1 year. Myeloproliferative neoplasm, aged 60–70 Symptoms: None reported. Free text:“I didn’t seek medical help for my blood disorder – it was detected ...
To characterize malignant cell states throughout disease progression, we used droplet-based scRNA-seq and profiled unselected, red blood cell-depleted cells derived from femoral BM of mice (Fig. 1a). After removing low-quality cells (see “Methods” for details, Supplementary Fig. 1a), we ...
Analysis and interpretation of data: AC-L, TE, CM, LVV, RO, MK, VS, FJP, BP, CEM, JS-M, JIM-S, AM, FP, and XA. Writing, review, and/or revision of the manuscript: AC-L, TE, JIM-S, AM, FP, XA, and all authors reviewed and approved the final version of the manuscript...